Clinical Trial

Current Status of Cardiovascular Diseases in Chinese Overweight/ Obesity Population: An Epidemiological Study (COPE)

Study acronym: COPE
Completed
View on ClinicalTrials.gov →
Summary
This study is testing how overweight and obesity affect cardiovascular disease (CVD) prevalence, risk factors, and mortality among Chinese adults using nationally representative CCDRFS (China Chronic Disease and Risk Factor Surveillance) data. The purpose of the study is to characterize trends and determinants of CVD in adults with overweight or obesity and to quantify the excess mortality and population burden attributable to overweight/obesity. Participants will not receive any study medicine as this is an observational analysis of existing survey and mortality data. The study does not involve a new investigational drug; it analyses health and outcome data collected in routine practice and national surveys. The study will last for the duration needed to analyse the CCDRFS datasets and linked mortality follow-up.
Trial Details
NCT Number NCT07358052
Lead Sponsor Novo Nordisk A/S
Conditions Obesity, Overweight
Enrollment 551,931 participants
Start Date 2025-12-08
Primary Completion 2025-12-12 (estimated)
Study Completion 2025-12-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-22